These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 31900184

  • 1. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis.
    Harries TH, Rowland V, Corrigan CJ, Marshall IJ, McDonnell L, Prasad V, Schofield P, Armstrong D, White P.
    Respir Res; 2020 Jan 03; 21(1):3. PubMed ID: 31900184
    [Abstract] [Full Text] [Related]

  • 2. Absolute Blood Eosinophil Counts to Guide Inhaled Corticosteroids Therapy Among Patients with COPD: Systematic Review and Meta-analysis.
    Oshagbemi OA, Odiba JO, Daniel A, Yunusa I.
    Curr Drug Targets; 2019 Jan 03; 20(16):1670-1679. PubMed ID: 31393244
    [Abstract] [Full Text] [Related]

  • 3. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
    Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, Disse B, Finnigan H, Calverley PM.
    Lancet Respir Med; 2016 May 03; 4(5):390-8. PubMed ID: 27066739
    [Abstract] [Full Text] [Related]

  • 4. Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis.
    Cheng SL.
    Int J Chron Obstruct Pulmon Dis; 2018 May 03; 13():2775-2784. PubMed ID: 30233168
    [Abstract] [Full Text] [Related]

  • 5. Blood eosinophils: a biomarker of COPD exacerbation reduction with inhaled corticosteroids.
    Siddiqui SH, Pavord ID, Barnes NC, Guasconi A, Lettis S, Pascoe S, Petruzzelli S.
    Int J Chron Obstruct Pulmon Dis; 2018 May 03; 13():3669-3676. PubMed ID: 30464449
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.
    Suissa S, Dell'Aniello S, Ernst P.
    Lancet Respir Med; 2018 Nov 03; 6(11):855-862. PubMed ID: 30343028
    [Abstract] [Full Text] [Related]

  • 8. Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD).
    Oshagbemi OA, Franssen FME, van Kraaij S, Braeken DCW, Wouters EFM, Maitland-van der Zee AH, Driessen JHM, de Vries F.
    COPD; 2019 Apr 03; 16(2):152-159. PubMed ID: 31117850
    [Abstract] [Full Text] [Related]

  • 9. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis.
    Pavord ID, Lettis S, Anzueto A, Barnes N.
    Lancet Respir Med; 2016 Sep 03; 4(9):731-741. PubMed ID: 27460163
    [Abstract] [Full Text] [Related]

  • 10. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials.
    Singh D, Wedzicha JA, Siddiqui S, de la Hoz A, Xue W, Magnussen H, Miravitlles M, Chalmers JD, Calverley PMA.
    Respir Res; 2020 Sep 17; 21(1):240. PubMed ID: 32943047
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Benefits and Risks of Inhaled Corticosteroid Treatment in Patients with Chronic Obstructive Pulmonary Disease Classified by Blood Eosinophil Counts.
    Saito Z, Yoshida M, Kojima A, Tamura K, Hasegawa T, Kuwano K.
    Lung; 2020 Dec 17; 198(6):925-931. PubMed ID: 33068153
    [Abstract] [Full Text] [Related]

  • 15. The distribution of blood eosinophil levels in a Japanese COPD clinical trial database and in the rest of the world.
    Barnes N, Ishii T, Hizawa N, Midwinter D, James M, Hilton E, Jones PW.
    Int J Chron Obstruct Pulmon Dis; 2018 Dec 17; 13():433-440. PubMed ID: 29440882
    [Abstract] [Full Text] [Related]

  • 16. Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population.
    Vestbo J, Vogelmeier CF, Small M, Siddall J, Fogel R, Kostikas K.
    Int J Chron Obstruct Pulmon Dis; 2019 Dec 17; 14():853-861. PubMed ID: 31114183
    [Abstract] [Full Text] [Related]

  • 17. Clinical implications of blood eosinophil count in patients with non-asthma-COPD overlap syndrome COPD.
    Song JH, Lee CH, Kim JW, Lee WY, Jung JY, Park JH, Jung KS, Yoo KH, Park YB, Kim DK.
    Int J Chron Obstruct Pulmon Dis; 2017 Dec 17; 12():2455-2464. PubMed ID: 28860740
    [Abstract] [Full Text] [Related]

  • 18. Association between COPD exacerbations and lung function decline during maintenance therapy.
    Kerkhof M, Voorham J, Dorinsky P, Cabrera C, Darken P, Kocks JW, Sadatsafavi M, Sin DD, Carter V, Price DB.
    Thorax; 2020 Sep 17; 75(9):744-753. PubMed ID: 32532852
    [Abstract] [Full Text] [Related]

  • 19. Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis.
    Hinds DR, DiSantostefano RL, Le HV, Pascoe S.
    BMJ Open; 2016 Jun 01; 6(6):e010099. PubMed ID: 27251682
    [Abstract] [Full Text] [Related]

  • 20. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
    Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID.
    Lancet Respir Med; 2015 Jun 01; 3(6):435-42. PubMed ID: 25878028
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.